Pfizer COVID-19 vaccine-associated tinnitus responds to transcranial magnetic stimulation

The Pfizer-BioNTech coronavirus illness 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine was among the many most celebrated breakthroughs of the continued pandemic. Together with the Moderna vaccine developed on the identical platform, the Pfizer-BioNTech vaccine has excessive efficacy towards symptomatic an infection and extreme COVID-19; nonetheless, it additionally has some severe, although unusual, adversarial results.

One uncommon aspect impact of the Pfizer-BioNTech COVID-19 vaccine is vaccine-associated tinnitus, which might scale back the standard of life. A brand new QJM: An Worldwide Journal of Drugs examine discusses one case by which this aspect impact was relieved with a short course of Transcranial Magnetic Stimulation (TMS) therapy.

Research: Pfizer–BioNTech COVID-19 Vaccine Related Tinnitus and Therapy with Transcranial Magnetic Stimulation. Picture Credit score: Picture Supply Buying and selling Ltd / Shutterstock.com

Introduction

Tinnitus related to the COVID-19 vaccine was first recognized after the intensive rollout of those vaccines. Initially, this aspect impact was thought to be an inflammatory vaccine-induced immune response. Steroids had been due to this fact thought of to be applicable administration to reverse the irritation, together with different anti-inflammatory brokers.

Finally, clinicians discovered that these sufferers didn’t report aid after a course of steroids, thus disproving the possibly inflammatory nature of this uncommon aspect impact.

Case examine

Within the present examine, a girl acquired two doses of the Pfizer-BioNTech vaccine. Whereas she first skilled bilateral tinnitus in 2020, it remained steady thereafter.

The affected person was managed for the situation with a tinnitus handicap index (THI) of 92, in 2021. Early that yr, a high-resolution computed tomography (HRCT) scan confirmed gentle irritation of the temporal bone, as with a earlier affected person. This was adopted up with baseline pure tone audiometry (PTA) that confirmed gentle sensorineural listening to loss at excessive excessive tones in the precise ear and mild-to-moderate loss within the left ear.

From mid-Might 2021, the affected person was prescribed a low dosage of the antibiotic ceftriaxone and reported a sluggish discount in tinnitus thereafter. The THI additionally decreased to 12 by the tip of September 2021.

A few month later, the affected person acquired her first dose of the vaccine and the second dose one month after. Whereas she didn’t have every other unwanted effects, her tinnitus started to worsen inside three days, particularly in the precise ear. The THI went up to 96.

The PTA was repeated, displaying extra extreme listening to loss that was once more extra intensive in the precise ear. She was thought to have a cochlear illness related to the vaccine and was prescribed the steroid protocol used on the authors’ heart.

Extra particularly, the affected person was prescribed a single 10 mg dose of dexamethasone intravenously adopted by 5 mg prednisolone 3 times a day for 3 days. This was given in the direction of the tip of December 2021. This therapy allowed the THI to barely lower to 88.

Initiation of rTMS

With out proof of serious aid, the affected person was began on repetitive TMS (rTMS) on February 16, 2022. She acquired 3,000 pulses over the realm of the left dorsolateral prefrontal cortex as soon as a day.

Encouragingly, she skilled aid. The THI decreased to 66 inside every week and, by March 9, 2021, her THI was 9. The repeat PTA carried out on the identical day exhibited a major enchancment within the listening to threshold from 11.2K to 16K.

That is among the many earliest case experiences the place rTMS has been used to deal with COVID-19-associated cochleopathy. The target proof of efficacy could also be noticed with the alterations within the PTA and THI, thus confirming the etiology and results of therapy with this modality.

Implications

An earlier meta-analysis confirmed that tinnitus with no particular trigger could possibly be handled by rTMS. Within the present case examine, rTMS relieved the situation that occurred following COVID-19 vaccination. This corroborates findings of earlier animal research, the place rTMS decreased irritation in each the goal and distant mind areas, seemingly on account of the immune response.

This might clarify why the tinnitus responded to the rTMS, which has an anti-inflammatory impact. Thus, rTMS could possibly be a viable different to steroid use in vaccine-associated tinnitus.

Importantly, the researchers emphasize that regardless of this adversarial impact, which they termed “minor and reversible”, the COVID-19 vaccine stays a advisable and secure alternative to defend people towards symptomatic and particularly extreme COVID-19.